William Blair Issues Pessimistic Outlook for BEAM Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Stock analysts at William Blair dropped their Q2 2025 EPS estimates for Beam Therapeutics in a note issued to investors on Tuesday, May 6th. William Blair analyst S. Corwin now forecasts that the company will post earnings per share of ($1.01) for the quarter, down from their previous estimate of ($0.94). The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. William Blair also issued estimates for Beam Therapeutics’ Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($4.09) EPS, Q1 2026 earnings at ($0.94) EPS, Q2 2026 earnings at ($0.98) EPS, Q3 2026 earnings at ($0.99) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($3.91) EPS.

Other equities research analysts have also issued reports about the company. Jones Trading upgraded Beam Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research note on Monday, March 10th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Beam Therapeutics in a research note on Monday, April 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Beam Therapeutics in a research note on Wednesday, March 12th. Wells Fargo & Company cut their price target on Beam Therapeutics from $75.00 to $70.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, Royal Bank of Canada lifted their price target on shares of Beam Therapeutics from $24.00 to $26.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $48.75.

Beam Therapeutics Stock Up 1.0 %

BEAM opened at $17.42 on Friday. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -9.90 and a beta of 2.35. The firm’s fifty day simple moving average is $20.07 and its two-hundred day simple moving average is $24.34. Beam Therapeutics has a 52-week low of $13.53 and a 52-week high of $35.25.

Beam Therapeutics (NASDAQ:BEAM) last announced its earnings results on Tuesday, May 6th. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.13). The business had revenue of $7.47 million for the quarter, compared to analyst estimates of $14.69 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.21) earnings per share.

Hedge Funds Weigh In On Beam Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. ARK Investment Management LLC lifted its position in shares of Beam Therapeutics by 20.0% during the first quarter. ARK Investment Management LLC now owns 8,480,089 shares of the company’s stock worth $165,616,000 after purchasing an additional 1,412,060 shares in the last quarter. Vanguard Group Inc. boosted its position in Beam Therapeutics by 16.4% in the 1st quarter. Vanguard Group Inc. now owns 8,871,292 shares of the company’s stock valued at $173,256,000 after buying an additional 1,249,303 shares during the last quarter. Casdin Capital LLC grew its stake in shares of Beam Therapeutics by 61.3% during the fourth quarter. Casdin Capital LLC now owns 1,250,000 shares of the company’s stock valued at $31,000,000 after acquiring an additional 475,000 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Beam Therapeutics by 11.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,957,611 shares of the company’s stock worth $98,149,000 after acquiring an additional 404,782 shares during the last quarter. Finally, Nikko Asset Management Americas Inc. lifted its stake in shares of Beam Therapeutics by 11.4% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,957,611 shares of the company’s stock worth $98,109,000 after acquiring an additional 404,782 shares in the last quarter. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Insider Activity at Beam Therapeutics

In other Beam Therapeutics news, President Giuseppe Ciaramella sold 7,434 shares of the firm’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total value of $136,413.90. Following the transaction, the president now directly owns 190,216 shares of the company’s stock, valued at $3,490,463.60. This trade represents a 3.76 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO John M. Evans sold 30,663 shares of the company’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total value of $562,666.05. Following the completion of the sale, the chief executive officer now directly owns 986,249 shares of the company’s stock, valued at $18,097,669.15. The trade was a 3.02 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,771 shares of company stock worth $803,198. 4.20% of the stock is owned by insiders.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.